Peripheral arterial disease is a common, under-treated and under-researched issue. The vast majority of these patients often have multiple issues which can be improved with targeted behavioural change interventions. NICE has recommended that supervised exercise is the mainstay of treatment for intermittent claudication (ischaemic muscle pain on walking due to blocked and narrowed arteries). However, in the vast majority of UK hospitals, this isn't undertaken, and with the issues around group-based sessions and repeated visits to hospitals, this treatment option is not available with the coronavirus pandemic. This is a single-centre randomised control trial in 60 patients with peripheral arterial disease attending the Freeman Hospital. Patients will be randomised to either an enhanced behavioural change intervention targeting multiple health behaviours vs a simple walking intervention. Also, some patients will be involved in focus groups to understand their experience of the intervention and whether it is feasible and acceptable, allowing changes to be made to the program. The primary outcome will be to assess the feasibility and acceptability of the program. We will also be assessing multiple secondary outcomes including functional capacity, quality of life, sleep quality and smoking and alcohol reduction.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Patients will undergo to weekly phone call/videoconference for 12 weeks and discuss the behaviour change. They also will undergo to home-based exercise training will be performed twice a week for 12 weeks via Zoom (up to 5 patients per session). Each session will be comprised of warm-up (10 min), the main part (15 to 20 min), and cooldown (5 to 10 min). The training aims to develop resistance, aerobic and functional capacity such as getting up, walking, pulling, pushing, throwing, transferring body weight or external loads. In addition, patients will be encouraged to increase their physical activity. Patients will be provided with a Fitbit device to monitor their step count and will be recommended to increase their previous week's average step count by 10%.
Freeman Hospital - Newcastle upon Tyne NHS trust
Newcastle upon Tyne, United Kingdom
Feasibility of the program
Feasibility will be determined by calculating the rate of patient screening, eligibility, recruitment, retention at 12 weeks and adherence to the intervention (number of sessions attended and completed)
Time frame: post 12 weeks
Acceptability of the program
Patient acceptability of the intervention and study experience more broadly will be determined through semi-structured qualitative 1-2-1 interviews and/or focus groups.
Time frame: post 12 weeks
Six-minute walk test (6MWT)
Time frame: pre and post-12 weeks
Walking Impairment Questionnaire (WIQ)
Time frame: pre and post-12 weeks
Walking Estimated Limitation Calculated by History (WELCH) questionnaire
Time frame: pre and post-12 weeks
Vascular quality of life questionnaire (VascuQoL-6)
Time frame: pre and post-12 weeks
EuroQoL questionnaire (EQ-5D-5L).
Time frame: pre and post-12 weeks
Short Form Dietary Questionnaire
Time frame: pre and post-12 weeks
Physical activity levels (Fitbit Charge HR)
Time frame: pre and post-12 weeks
Sleep
(Fitbit Charge HR)
Time frame: pre and post-12 weeks
Alcohol and tobacco use
The 3-item Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) and self-reported smoking habits
Time frame: pre and post-12 weeks
Mental wellbeing
hospital anxiety-depression score (HADS)
Time frame: pre and post-12 weeks
Patient activation
The Patient Activation Measure (PAM®)
Time frame: pre and post-12 weeks
Resource utilisation
The case report forms (CRF)
Time frame: pre and post-12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.